Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study

Ahmed AK Hassoun,1 Md Faruque Pathan,2 Rita C Medlej,3,4 Monira Alarouj,5 Inass Shaltout,6 Manoj S Chawla,7 Ditte Knap,8 Julius A Vaz9 1Dubai Diabetes Centre, Dubai, UAE; 2Department of Endocrinology, BIRDEM Hospital, Dhaka, Bangladesh; 3Department of Endocrinology, Hotel Dieu de France Hospital, 4C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hassoun AAK, Pathan MF, Medlej RC, Alarouj M, Shaltout I, Chawla MS, Knap D, Vaz JA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	age metformin Ramadan sulfonylurea type 2 diabetes vildagliptin Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/143b0bf2343345a18b60407c25bca396
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:143b0bf2343345a18b60407c25bca396
record_format	dspace
spelling	oai:doaj.org-article:143b0bf2343345a18b60407c25bca3962021-12-02T00:34:51ZEffects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study1178-7007https://doaj.org/article/143b0bf2343345a18b60407c25bca3962016-07-01T00:00:00Zhttps://www.dovepress.com/effects-of-vildagliptin-relative-to-sulfonylureas-in-muslim-patients-w-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Ahmed AK Hassoun,1 Md Faruque Pathan,2 Rita C Medlej,3,4 Monira Alarouj,5 Inass Shaltout,6 Manoj S Chawla,7 Ditte Knap,8 Julius A Vaz9 1Dubai Diabetes Centre, Dubai, UAE; 2Department of Endocrinology, BIRDEM Hospital, Dhaka, Bangladesh; 3Department of Endocrinology, Hotel Dieu de France Hospital, 4Chronic Care Centre, Saint Joseph University, Beirut, Lebanon; 5Dasman Diabetes Institute, Dasman, Kuwait; 6Faculty of Medicine, Cairo University, Cairo, Egypt; 7Lina Diabetes Care Centre, Mumbai, India; 8Novartis Pharma AG, Basel, Switzerland; 9Novartis Healthcare Private Limited, Hyderabad, India Background: VIRTUE was a prospective, observational study assessing the effectiveness and safety of vildagliptin vs sulfonylureas (SUs) (both as monotherapy and in combination with metformin) in patients with type 2 diabetes mellitus who fasted during Ramadan. A post hoc analysis was carried out to assess the effect of treatment with/without metformin and age (<65 years or ≥65 years). Patients and methods: Patients were recruited from the Middle East and Asia. The primary end point was proportion of patients with one or more hypoglycemic event (HE) during Ramadan. Secondary end points included change from baseline in glycated hemoglobin (HbA1c), body weight, and safety. Results: Overall, 684 patients received vildagliptin and 631 received SUs. Most patients received dual therapy with metformin (n=1,148) and were aged <65 years (n=1,189). A few patients experienced one or more HE with vildagliptin vs SU monotherapy (6.5% vs 14.5%) and with vildagliptin + metformin vs SUs + metformin (5.3% vs 20.6%); the latter achieved statistical significance (P<0.001) in both age subgroups (<65 years: 5.5% vs 18.4%, P<0.001; ≥65 years: 2.8% vs 30.9%, P<0.001). Vildagliptin was associated with numerically greater HbA1c and body weight reductions vs SUs, regardless of the therapy type or age. A higher proportion of SU- vs vildagliptin-treated patients experienced adverse events across all subgroups. Conclusion: A few patients experienced HEs with vildagliptin vs SUs regardless of age, and in patients on dual therapy. Vildagliptin ± metformin was also associated with good glycemic and weight control and was well tolerated. Vildagliptin might be a useful treatment option for patients with type 2 diabetes mellitus, particularly high-risk populations such as the elderly fasting during Ramadan. Keywords: age, metformin, Ramadan, sulfonylurea, type 2 diabetes, vildagliptinHassoun AAKPathan MFMedlej RCAlarouj MShaltout IChawla MSKnap DVaz JADove Medical PressarticleagemetforminRamadansulfonylureatype 2 diabetesvildagliptinSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 225-232 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	age metformin Ramadan sulfonylurea type 2 diabetes vildagliptin Specialties of internal medicine RC581-951
spellingShingle	age metformin Ramadan sulfonylurea type 2 diabetes vildagliptin Specialties of internal medicine RC581-951 Hassoun AAK Pathan MF Medlej RC Alarouj M Shaltout I Chawla MS Knap D Vaz JA Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study
description	Ahmed AK Hassoun,1 Md Faruque Pathan,2 Rita C Medlej,3,4 Monira Alarouj,5 Inass Shaltout,6 Manoj S Chawla,7 Ditte Knap,8 Julius A Vaz9 1Dubai Diabetes Centre, Dubai, UAE; 2Department of Endocrinology, BIRDEM Hospital, Dhaka, Bangladesh; 3Department of Endocrinology, Hotel Dieu de France Hospital, 4Chronic Care Centre, Saint Joseph University, Beirut, Lebanon; 5Dasman Diabetes Institute, Dasman, Kuwait; 6Faculty of Medicine, Cairo University, Cairo, Egypt; 7Lina Diabetes Care Centre, Mumbai, India; 8Novartis Pharma AG, Basel, Switzerland; 9Novartis Healthcare Private Limited, Hyderabad, India Background: VIRTUE was a prospective, observational study assessing the effectiveness and safety of vildagliptin vs sulfonylureas (SUs) (both as monotherapy and in combination with metformin) in patients with type 2 diabetes mellitus who fasted during Ramadan. A post hoc analysis was carried out to assess the effect of treatment with/without metformin and age (<65 years or ≥65 years). Patients and methods: Patients were recruited from the Middle East and Asia. The primary end point was proportion of patients with one or more hypoglycemic event (HE) during Ramadan. Secondary end points included change from baseline in glycated hemoglobin (HbA1c), body weight, and safety. Results: Overall, 684 patients received vildagliptin and 631 received SUs. Most patients received dual therapy with metformin (n=1,148) and were aged <65 years (n=1,189). A few patients experienced one or more HE with vildagliptin vs SU monotherapy (6.5% vs 14.5%) and with vildagliptin + metformin vs SUs + metformin (5.3% vs 20.6%); the latter achieved statistical significance (P<0.001) in both age subgroups (<65 years: 5.5% vs 18.4%, P<0.001; ≥65 years: 2.8% vs 30.9%, P<0.001). Vildagliptin was associated with numerically greater HbA1c and body weight reductions vs SUs, regardless of the therapy type or age. A higher proportion of SU- vs vildagliptin-treated patients experienced adverse events across all subgroups. Conclusion: A few patients experienced HEs with vildagliptin vs SUs regardless of age, and in patients on dual therapy. Vildagliptin ± metformin was also associated with good glycemic and weight control and was well tolerated. Vildagliptin might be a useful treatment option for patients with type 2 diabetes mellitus, particularly high-risk populations such as the elderly fasting during Ramadan. Keywords: age, metformin, Ramadan, sulfonylurea, type 2 diabetes, vildagliptin
format	article
author	Hassoun AAK Pathan MF Medlej RC Alarouj M Shaltout I Chawla MS Knap D Vaz JA
author_facet	Hassoun AAK Pathan MF Medlej RC Alarouj M Shaltout I Chawla MS Knap D Vaz JA
author_sort	Hassoun AAK
title	Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study
title_short	Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study
title_full	Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study
title_fullStr	Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study
title_full_unstemmed	Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study
title_sort	effects of vildagliptin relative to sulfonylureas in muslim patients with type 2 diabetes fasting during ramadan: influence of age and treatment with/without metformin in the virtue study
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/143b0bf2343345a18b60407c25bca396
work_keys_str_mv	AT hassounaak effectsofvildagliptinrelativetosulfonylureasinmuslimpatientswithtype2diabetesfastingduringramadaninfluenceofageandtreatmentwithwithoutmetformininthevirtuestudy AT pathanmf effectsofvildagliptinrelativetosulfonylureasinmuslimpatientswithtype2diabetesfastingduringramadaninfluenceofageandtreatmentwithwithoutmetformininthevirtuestudy AT medlejrc effectsofvildagliptinrelativetosulfonylureasinmuslimpatientswithtype2diabetesfastingduringramadaninfluenceofageandtreatmentwithwithoutmetformininthevirtuestudy AT alaroujm effectsofvildagliptinrelativetosulfonylureasinmuslimpatientswithtype2diabetesfastingduringramadaninfluenceofageandtreatmentwithwithoutmetformininthevirtuestudy AT shaltouti effectsofvildagliptinrelativetosulfonylureasinmuslimpatientswithtype2diabetesfastingduringramadaninfluenceofageandtreatmentwithwithoutmetformininthevirtuestudy AT chawlams effectsofvildagliptinrelativetosulfonylureasinmuslimpatientswithtype2diabetesfastingduringramadaninfluenceofageandtreatmentwithwithoutmetformininthevirtuestudy AT knapd effectsofvildagliptinrelativetosulfonylureasinmuslimpatientswithtype2diabetesfastingduringramadaninfluenceofageandtreatmentwithwithoutmetformininthevirtuestudy AT vazja effectsofvildagliptinrelativetosulfonylureasinmuslimpatientswithtype2diabetesfastingduringramadaninfluenceofageandtreatmentwithwithoutmetformininthevirtuestudy
_version_	1718403599352987648

Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study

Ejemplares similares